• Asian Pacific Journal of Cancer Prevention
• /
• 제17권7호
• /
• pp.3465-3468
• /
• 2016

Background: Fluorodeoxyglucose ($^{18}FDG$) PET/CT imaging has become an important component of the management paradigm in oncology. However, the significant imparted radiation exposure is a matter of growing concern especially in younger populations who have better odds of survival. The aim of this study was to estimate the effective dose received by patients having whole body $^{18}F$-FDG PET/CT scanning as per recent dose reducing guidelines at a tertiary care hospital. Materials and Methods: This prospective study covered 63 patients with different cancers who were referred for PET/CT study for various indications. Patients were prepared as per departmental protocol and 18FDG was injected at 3 MBq/Kg and a low dose, non-enhanced CT protocol (LD-NECT) was used. Diagnostic CT studies of specific regions were subsequently performed if required. Effective dose imparted by 18FDG (internal exposure) was calculated by using multiplying injected dose in MBq with coefficient $1.9{\times}10^{-2}mSv/MBq$ according to ICRP publication 106. Effective dose imparted by CT was calculated by multiplying DLP (mGy.cm) with ICRP conversion coefficient "k" 0.015 [mSv / (mG. cm)]. Results: Mean age of patients was $49{\pm}18$ years with a male to female ratio of 35:28 (56%:44%). Median dose of 18FDG given was 194 MBq (range: 139-293). Median CTDIvol was 3.25 (2.4-6.2) and median DLP was 334.95 (246.70 - 576.70). Estimated median effective dose imparted by $^{18}FDG$ was 3.69 mSv (range: 2.85-5.57). Similarly the estimated median effective dose by low dose (non-diagnostic) CT examination was 4.93 mSv (range: 2.14 -10.49). Median total effective dose by whole body 18FDG PET plus low dose non-diagnostic CT study was 8.85 mSv (range: 5.56-13.00). Conclusions: We conclude that the median effective dose from a whole body 18FDG PET/CT in our patients was significantly low. We suggest adhering to recently published dose reducing strategies, use of ToF scanner with CT dose reducing option to achieve the lower if not the lowest effective dose. This would certainly reduce the risk of second primary malignancy in younger patients with higher odds of cure from first primary cancer.

• 한국컴퓨터정보학회논문지
• /
• 제26권8호
• /
• pp.197-207
• /
• 2021

2형 당뇨병환자에서 골밀도는 다양하게 보고되고 있다. 최근의 여러 역학조사 연구에 의하면 2형 당뇨병 환자에서 골밀도 상태와 무관하게 골절 위험이 증가한다는 보고들이 많다. 본 연구에서는 전국민을 대상으로 한 표본조사로부터 얻은 질병관리본부의 국민건강영양조사 2008-2011년 자료를 이용하여 2형 당뇨병이 있는 50세 이상 남성 및 폐경후여성에서 골밀도를 확인하고자 하였다. 골다공증약물을 사용한 경우 및 당뇨병 이외에 골밀도에 영향을 미치는 질환 및 악성질환 등이 있는 대상은 제외하였다. 신체계측, 설문조사, 혈액검사 등과 함께 이중에너지흡수방사선을 이용하여 요추 및 대퇴골에서 측정한 골밀도 결과를 이용하였다. 연령, 체질량지수, 월 가구수입, 교육수준, 신체활동, 1일 칼슘섭취량, 혈중 비타민 D 농도를 포함하는 다중회귀분석을 시행한 결과 2형 당뇨병이 있는 50세 이상 남성 및 폐경후여성 모두에서 당뇨병이 없는 군과 비교하여 요추골밀도가 유의하게 높게 나타났다.